May 3, 2011 — A guideline document from the American Society of Echocardiography (ASE) which makes recommendations for the use of current imaging modalities in optimizing the management of patients with hypertrophic cardiomyopathy (HCM) has been published in the May issue of JASE, the Journal of the ASE. “The document includes the recommendations for the role of imaging in the diagnosis and followup of patients with hypertrophic cardiomyopathy, including risk stratification for sudden cardiac death,” explained writing group chair Sherif F. Nagueh, M.D., FASE, professor of medicine at Weill Cornell Medical College and the medical director of the Methodist DeBakey Heart & Vascular Center Echocardiography laboratory in Houston, Texas.

Advances in cardiac imaging have brought an increasing complexity of imaging choices for busy clinicians to consider. Clinicians can image the heart using ultrasound, magnetic resonance imaging (MRI), computed tomography (CT) or nuclear cardiology techniques. Physicians need to make appropriate choices among the imaging options to avoid duplicate testing or getting studies which don’t address the clinical question.

Unlike many guideline documents, which focus on a specific type of cardiac imaging, this paper brings together experts across all types of cardiac imaging to focus on a specific clinical disorder. This guideline reviews the strengths and weakness of the different ways to image the heart in patients with HCM. By taking a critical look at the most commonly used cardiac imaging modalities and most common clinical questions in patients with HCM, this guideline should prove to be a valuable resource.

HCM is the most common genetic cardiomyopathy, affecting about 0.2 percent of people across multiple geographies and ethnicities. While a majority of patients with HCM have a near normal lifespan, adverse outcomes, including life-limiting symptoms and sudden cardiac death, occur in some people.

The recommendations were endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography. The full document is available at www.asecho.org/guidelines.

The American Society of Echocardiography (ASE) is a professional organization of physicians, cardiac sonographers, nurses and scientists involved in echocardiography, the use of ultrasound to image the heart and cardiovascular system. The organization was founded in 1975 and is the largest international organization for cardiac imaging.

For more information: www.asecho.org


Related Content

News | Artificial Intelligence

June 15, 2026 — HOPPR recently announced that HOPPR AI Foundry is now available in AWS Marketplace. The availability ...

Time June 19, 2026
arrow
News | Digital Pathology

June 15, 2026 — Leica Biosystems is expanding the availability of its Aperio GT Elite digital scanner into the EMEA ...

Time June 15, 2026
arrow
News | Radiology Business

June 9, 2026 — Bayer has appointed Dr. Jost Reinhard president of the Radiology business within Bayer’s Pharmaceuticals ...

Time June 12, 2026
arrow
News | Enterprise Imaging

June 9, 2026 — GE HealthCare will showcase its latest enterprise imaging solutions at the Society for Imaging ...

Time June 09, 2026
arrow
News | Innovative Hospitals

May 27, 2026 — Nearly two years after announcing plans for a “real-world” academic-industrial collaboration, GE ...

Time June 03, 2026
arrow
News | Nuclear Imaging

June 1, 2026 — At the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, GE HealthCare will ...

Time June 02, 2026
arrow
News | Radiology Business

May 22, 2026 — The American College of Radiology (ACR) supports passage of the Medicare Access to Radiology Care Act (S ...

Time May 26, 2026
arrow
News | Radiology Business

May 22, 2026 — U.S. Sens. Boozman, R-AR, and Luján, D-NM, have introduced the Medicare Access to Radiology Care Act ...

Time May 26, 2026
arrow
Feature | Enterprise Imaging | Kyle Hardner

For radiology departments, the imbalance between surging imaging volume and a shortage of trained radiologists is taking ...

Time May 20, 2026
arrow
News | Radiopharmaceuticals and Tracers

May 7, 2026 — Bayer has announced positive topline results from the Phase III REVEAL study, an investigator-initiated ...

Time May 08, 2026
arrow
Subscribe Now